{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:41:09Z","timestamp":1792806069388,"version":"4.5.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017584","name":"SRM Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017584","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bbrep.2025.102278","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T23:15:09Z","timestamp":1759878909000},"page":"102278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Role of T cells and cytokines in the pathogenesis of rheumatoid arthritis"],"prefix":"10.1016","volume":"44","author":[{"given":"Monisha","family":"Anandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-2761","authenticated-orcid":false,"given":"J.","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2025.102278_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101974","article-title":"Pharmacogenetics of therapies in rheumatoid arthritis: an update","author":"Babiker-Mohamed","year":"2024","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102278_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28127","article-title":"Exosomes and exosomal miRNAs: a new avenue for the future treatment of rheumatoid arthritis","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"issue":"10","key":"10.1016\/j.bbrep.2025.102278_bib3","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"5","author":"Black","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.crbiot.2024.100220","article-title":"Investigating the anti-inflammatory and anti-arthritis effects of fucoidan from a brown seaweed","author":"Raj","year":"2024","journal-title":"Current Res. Biotechnol."},{"key":"10.1016\/j.bbrep.2025.102278_bib5","article-title":"Traditional medicinal plants used for rheumatoid arthritis and immune system disorders treatment in the Casablanca-Settat region, Morocco: an ethnopharmacological study","volume":"11","author":"Sekkout","year":"2024","journal-title":"Eur. J. Med. Chem. Rep."},{"issue":"12","key":"10.1016\/j.bbrep.2025.102278_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32832","article-title":"Bibliometric analysis of the top 100 most cited articles on Th17\/Treg balance and rheumatoid arthritis","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrep.2025.102278_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105732","article-title":"Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis","author":"Bhavsar","year":"2024","journal-title":"Jt. Bone Spine"},{"issue":"13","key":"10.1016\/j.bbrep.2025.102278_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33706","article-title":"Chinese traditional medicine DZGP beneficially affects gut microbiome, serum metabolites and recovery from rheumatoid arthritis through mediating NF-\u03baB signaling pathway","volume":"10","author":"Zhao","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib9","article-title":"Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.bbrep.2025.102278_bib10","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/cells9081852","article-title":"Mesenchymal stem\/stromal cells for rheumatoid arthritis treatment: an update on clinical applications","volume":"9","author":"Lopez-Santalla","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbrep.2025.102278_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102726","article-title":"Kinase activity profiling reveals contribution of G-protein signaling modulator 2 deficiency to impaired regulatory T cell migration in rheumatoid arthritis","volume":"124","author":"Meyer","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bbrep.2025.102278_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/cancers8030036","article-title":"Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy","volume":"8","author":"Golubovskaya","year":"2016","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.bbrep.2025.102278_bib15","first-page":"269","article-title":"Biomaterial-enhanced treg cell immunotherapy: a promising approach for transplant medicine and autoimmune disease treatment","volume":"37","author":"Mashayekhi","year":"2024","journal-title":"Bioact. Mater."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.bbrep.2025.102278_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30553","article-title":"Helper T cell subsets: development, function and clinical role in hypersensitivity reactions in the modern perspective","volume":"10","author":"Kan","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrep.2025.102278_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116440","article-title":"Exploring the therapeutic potential of regulatory T cell in rheumatoid arthritis: insights into subsets, markers, and signaling pathways","volume":"174","author":"Su","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/13543776.12.3.341","article-title":"Modulation of Th1 and Th2 responses for immunotherapy","volume":"12","author":"Dumont","year":"2002","journal-title":"Expert Opin. Ther. Pat."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26359","article-title":"Regulatory role of T helper 9\/interleukin-9: transplantation view","volume":"10","author":"Roostaee","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrep.2025.102278_bib21","article-title":"Abatacept inhibits Th17 differentiation and mitigates \u03b1-synuclein-induced dopaminergic dysfunction in mice","author":"Clarke","year":"2024","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.bbrep.2025.102278_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572858","article-title":"TH17\/Treg-Related transcriptional factor expression and cytokine profile in patients with rheumatoid arthritis","volume":"11","author":"Paradowska-Gorycka","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102278_bib23","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin\u20106 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.bbrep.2025.102278_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrep.2025.102278_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/ar3152","article-title":"Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-alpha co-expression, but little interleukin-22 and interleukin-23R expression","volume":"12","author":"Church","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib26","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192048","article-title":"Interleukin-17 in rheumatoid arthritis: trials and tribulations","volume":"217","author":"Taams","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrep.2025.102278_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1161148","article-title":"The role of dendritic cells and their immunometabolism in rheumatoid arthritis","volume":"14","author":"Suwa","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13075-023-03159-8","article-title":"The mechanism of dendritic cell-T cell crosstalk in rheumatoid arthritis","volume":"25","author":"Wang","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbrep.2025.102278_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101940","article-title":"Dendritic cells and antigen-specific immunotherapy in autoimmune rheumatic diseases","author":"Cai","year":"2024","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115574","article-title":"Reprogramming the lipid metabolism of dendritic cells in tumor immunomodulation and immunotherapy","volume":"167","author":"Sun","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.bbrep.2025.102278_bib31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrrheum.2009.185","article-title":"Dendritic cells as targets for therapy in rheumatoid arthritis","volume":"5","author":"Khan","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102278_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29686","article-title":"Monocytes and macrophages: origin, homing, differentiation, and functionality during inflammation","volume":"10","author":"Dash","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrep.2025.102278_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122943","article-title":"Engineering M2 macrophage-derived exosomes modulate activated T cell cuproptosis to promote immune tolerance in rheumatoid arthritis","volume":"315","author":"Wu","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrep.2025.102278_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114426","article-title":"Emerging role of macrophages in non-infectious diseases: an update","volume":"161","author":"Yousaf","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"Pt 2","key":"10.1016\/j.bbrep.2025.102278_bib35","article-title":"Photodriven PtPdCo-TiO2 heterostructure modified with hyaluronic acid and folic acid enhances antioxidative stress through efficient hydrogen\/oxygen delivery and thermal effects in rheumatoid arthritis therapy","volume":"307","author":"Wu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102278_bib36","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.3390\/ijms25052688","article-title":"Osteoimmunology: the crosstalk between T cells, B cells, and osteoclasts in rheumatoid arthritis","volume":"25","author":"Yang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","article-title":"B cell development pathways","volume":"19","author":"Hardy","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrep.2025.102278_bib40","article-title":"B cells in rheumatoid arthritis:pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2025.102278_bib41","article-title":"New potential therapeutic approaches targeting synovial fibroblasts in rheumatoid arthritis","volume":"194","author":"Alcaraz","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102278_bib42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kel065","article-title":"Synovial fibroblasts: key players in rheumatoid arthritis","volume":"45","author":"Huber","year":"2006","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102278_bib43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/ar113","article-title":"Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis","volume":"2","author":"Pap","year":"2000","journal-title":"Arthritis Res."},{"key":"10.1016\/j.bbrep.2025.102278_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncprheum0142","article-title":"T-cell-targeted therapies in rheumatoid arthritis","volume":"2","author":"Weyand","year":"2006","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102278_bib45","article-title":"Biomarkers in rheumatoid arthritis","volume":"13","author":"Shapiro","year":"2021","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101812","article-title":"Personalized medicine in rheumatoid arthritis: combining biomarkers and patient preferences to guide therapeutic decisions","volume":"36","author":"Thomas","year":"2022","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jfma.2020.04.004","article-title":"The PD-1\/PD-L pathway in rheumatic diseases","volume":"120","author":"Zhang","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.bbrep.2025.102278_bib48","article-title":"Programmed death ligand 2 \u2013 a link between inflammation and bone loss in rheumatoid arthritis","volume":"3","author":"Greisen","year":"2020","journal-title":"J. Transl. Autoimm."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejr.2014.12.002","article-title":"Clinical significance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients: relation to disease activity and functional status","volume":"37","author":"Hassan","year":"2015","journal-title":"The Egyptian Rheumatologist"},{"key":"10.1016\/j.bbrep.2025.102278_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105948","article-title":"Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study","volume":"166","author":"Wu","year":"2020","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejr.2013.03.005","article-title":"Deficient or abundant but unable to fight? Estimation of circulating FoxP3+ T regulatory cells and their counteracting FoxP3\u2212 in rheumatoid arthritis and correlation with disease activity","volume":"35","author":"Abaza","year":"2013","journal-title":"Egyptian Rheumatol. Egyptian Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107338","article-title":"Role of Forkhead box O3a transcription factor in autoimmune diseases","volume":"92","author":"Xu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbrep.2025.102278_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104603","article-title":"Magnesium increases numbers of Foxp3+ Treg cells and reduces arthritis severity and joint damage in an IL-10-dependent manner mediated by the intestinal microbiome","volume":"92","author":"Laragione","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejr.2014.06.004","article-title":"FoxP3+T regulatory cells in Rheumatoid arthritis and the imbalance of the Treg\/TH17 cytokine axis","volume":"37","author":"Al-Zifzaf","year":"2014","journal-title":"The Egyptian Rheumatologist"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.slast.2024.100146","article-title":"Nanomaterials in the treatment and diagnosis of rheumatoid arthritis: advanced approaches","volume":"29","author":"Angela","year":"2024","journal-title":"SLAS Technol."},{"key":"10.1016\/j.bbrep.2025.102278_bib56","author":"Wei"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18053\/jctres.02.201603.005","article-title":"The role of TNF-\u03b1 in rheumatoid arthritis: a focus on regulatory T cells","volume":"2","author":"Farrugia","year":"2016","journal-title":"J. Clin. Transl. Res."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12967-025-06122-0","article-title":"Exploring TNFR1: from discovery to targeted therapy development","volume":"23","author":"Li","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1808-8694(15)31133-2","article-title":"The role of Tumor necrosis Factor -Alpha (TNF-\u03b1) in bone resorption present in middle ear cholesteatoma","volume":"73","author":"Vitale","year":"2007","journal-title":"Brazilian J. Otorhinolaryngol."},{"key":"10.1016\/j.bbrep.2025.102278_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116540","article-title":"Cytokine-mediated immunomodulation of osteoclastogenesis","volume":"164","author":"Zhou","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.bbrep.2025.102278_bib61","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2025.102278_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2025.102187","article-title":"Clinical application of biological agents in rheumatoid arthritis","author":"Cheng","year":"2025","journal-title":"Transpl. Immunol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102278_bib63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2332\/allergolint.54.191","article-title":"Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases","volume":"54","author":"Takeuchi","year":"2005","journal-title":"Allergol. Int."},{"key":"10.1016\/j.bbrep.2025.102278_bib64","doi-asserted-by":"crossref","unstructured":"J. Kuai, Z. Chen, J. He, F. Wang, W. Wei, Promising TNF-\u03b1 inhibitors: targeting pathogenic TNF-\u03b1\/TNFR signaling to restore Th17\/Treg balance in rheumatoid arthritis, J. Pharm. Anal., https:\/\/doi.org\/10.1016\/j.jpha.2025.101382.","DOI":"10.1016\/j.jpha.2025.101382"},{"key":"10.1016\/j.bbrep.2025.102278_bib65","article-title":"Knockdown of Galectin-9 alleviates rheumatoid arthritis through suppressing TNF-\u03b1-induced activation of fibroblast-like synoviocytes","volume":"220","author":"Jia","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152382","article-title":"IL-37 alleviates TNF-\u03b1-induced pyroptosis of rheumatoid arthritis fibroblast-like synoviocytes by inhibiting the NF-\u03baB\/GSDMD signaling pathway","volume":"228","author":"Ren","year":"2023","journal-title":"Immunobiology"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102278_bib67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2332\/allergolint.10-RAI-0186","article-title":"IL-33 and IL-33 receptors in host defense and diseases","volume":"59","author":"Oboki","year":"2010","journal-title":"Allergol. Int."},{"key":"10.1016\/j.bbrep.2025.102278_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110770","article-title":"Potential mechanistic roles of Interleukin-33 in rheumatoid arthritis","volume":"123","author":"Ouyang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbrep.2025.102278_bib69","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/587376","article-title":"Role of IL-33 and its receptor in T cell-mediated autoimmune diseases","volume":"2014","author":"Zhao","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.bbrep.2025.102278_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115143","article-title":"IL-33\/ST2 signaling in pain and itch: cellular and molecular mechanisms and therapeutic potentials","volume":"165","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"15","key":"10.1016\/j.bbrep.2025.102278_bib71","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3390\/ijms21155238","article-title":"Interleukin-6 in rheumatoid arthritis","volume":"21","author":"Pandolfi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2025.102278_bib72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbrep.2025.102278_bib73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41540-023-00308-2","article-title":"Experiment-based computational model predicts that IL-6 classic and trans-signaling exhibit similar potency in inducing downstream signaling in endothelial cells","volume":"9","author":"Song","year":"2023","journal-title":"npj Syst. Biol. Appl."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","article-title":"Understanding the role of Interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis","volume":"7","author":"Favalli","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.bbrep.2025.102278_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ntm.2024.100051","article-title":"Phytomedicine meets nanotechnology: a cellular approach to rheumatoid arthritis treatment","author":"Shukla","year":"2024","journal-title":"Nano TransMed."},{"key":"10.1016\/j.bbrep.2025.102278_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241283340","article-title":"What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?","volume":"16","author":"Taylor","year":"2024","journal-title":"Ther. Adv. Musculoskelet Dis."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102278_bib77","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood-2008-12-164004","article-title":"The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease","volume":"114","author":"Hercus","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrep.2025.102278_bib78","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41232-016-0014-5","article-title":"GM-CSF as a therapeutic target in autoimmune diseases","volume":"36","author":"Shiomi","year":"2016","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.bbrep.2025.102278_bib79","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/568543","article-title":"Pivotal roles of GM-CSF in autoimmunity and inflammation","volume":"2015","author":"Shiomi","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bbrep.2025.102278_bib80","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S262566","article-title":"GM-CSF: a promising target in inflammation and autoimmunity","volume":"9","author":"Lee","year":"2020","journal-title":"ImmunoTargets Ther."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102278_bib81","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(20)30352-0","article-title":"The efficacy and safety of targeting GM-CSF in arthritis","volume":"2","author":"Bykerk","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"Suppl 3","key":"10.1016\/j.bbrep.2025.102278_bib82","doi-asserted-by":"crossref","first-page":"iii29","DOI":"10.1136\/ard.2006.058529","article-title":"Potential new targets in arthritis therapy: Interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis","volume":"65","author":"Koenders","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib83","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12920-023-01713-6","article-title":"Genetic association between interleukin-17 and susceptibility to rheumatoid arthritis","volume":"16","author":"Zhao","year":"2023","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.bbrep.2025.102278_bib84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cellimm.2018.09.001","article-title":"IL-17 and limits of success","volume":"339","author":"Omidian","year":"2019","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12026-021-09173-9","article-title":"Effect of interleukin-6, -17, -21, -22, and -23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis","volume":"69","author":"Wo\u015b","year":"2021","journal-title":"Immunol. Res."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib86","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1759720X13485328","article-title":"Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential","volume":"5","author":"Kellner","year":"2013","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"10.1016\/j.bbrep.2025.102278_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102689","article-title":"New developments implicating IL-21 in autoimmune disease","volume":"122","author":"Ren","year":"2021","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7150\/ijbs.5996","article-title":"Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis","volume":"9","author":"Carbone","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbrep.2025.102278_bib89","article-title":"The role of Interleukin-21 in autoimmune diseases: mechanisms, therapeutic implications, and future directions","volume":"173","author":"Shbeer","year":"2023","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102278_bib90","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/jcp.26158","article-title":"Multifaceted role of IL-21 in rheumatoid arthritis: current understanding and future perspectives","volume":"233","author":"Dinesh","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102278_bib91","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.4049\/jimmunol.1301173","article-title":"The cellular source and target of IL-21 in K\/BxN autoimmune arthritis","volume":"191","author":"Block","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib92","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/sji.12396","article-title":"Interleukin-21 induces proliferation and proinflammatory cytokine profile of fibroblast-like synoviocytes of patients with rheumatoid arthritis","volume":"83","author":"Xing","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.bbrep.2025.102278_bib93","article-title":"Anti-rheumatoid drugs advancements: new insights into the molecular treatment of rheumatoid arthritis","volume":"151","author":"Mrid","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib94","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib95","first-page":"225","article-title":"Methotrexate: implications of pharmacogenetics in the treatment of patients with rheumatoid arthritis","volume":"1","author":"Torres","year":"2022","journal-title":"ARP Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113074","article-title":"Application and pharmacological mechanism of methotrexate in rheumatoid arthritis","volume":"150","author":"Zhao","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102278_bib97","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate: a randomized trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bbrep.2025.102278_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30393","article-title":"Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus","author":"Peng-Cheng","year":"2024","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.bbrep.2025.102278_bib99","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s40620-023-01733-6","article-title":"Hydroxychloroquine in nephrology: current status and future directions","volume":"36","author":"Rao","year":"2023","journal-title":"J. Nephrol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102278_bib100","article-title":"Antimalarials for rheumatoid arthritis","volume":"2000","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib101","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijwd.2020.01.009","article-title":"Sulfasalazine in dermatology: a lesser explored drug with broad therapeutic potential","volume":"6","author":"Mushtaq","year":"2020","journal-title":"Int. J. Womens Dermatol."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib102","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF02031270","article-title":"The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine","volume":"3","author":"Farr","year":"1984","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib103","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bbrep.2025.102278_bib104","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.3390\/ijms25158327","article-title":"JAK inhibitors in rheumatoid arthritis: immunomodulatory properties and clinical efficacy","volume":"25","author":"Kie\u0142bowski","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.bbrep.2025.102278_bib105","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.bbrep.2025.102278_bib106","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.bbrep.2025.102278_bib107","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5114\/reum.2020.102006","article-title":"Baricitinib for the treatment of rheumatoid arthritis","volume":"58","author":"Urits","year":"2020","journal-title":"Reumatologia"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102278_bib108","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","article-title":"A review of upadacitinib in rheumatoid arthritis","volume":"30","author":"Tanaka","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib109","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/jcm12051734","article-title":"Upadacitinib for patients with rheumatoid arthritis: a comprehensive review","volume":"12","author":"Sanmart\u00ed","year":"2023","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102278_bib110","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1080\/03007995.2024.2416979","article-title":"Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data","volume":"40","author":"Edwards","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102278_bib111","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/art.42547","article-title":"Differences in JAK isoform selectivity among different types of JAK inhibitors evaluated for rheumatic diseases through in vitro profiling","volume":"75","author":"Virtanen","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib112","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/children11091146","article-title":"Single center-based real-world experience on Anti-IL 1 biological response modifiers: a case series and literature review","volume":"11","author":"Jones","year":"2024","journal-title":"Children"},{"key":"10.1016\/j.bbrep.2025.102278_bib113","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/annrheumdis-2021-221801","volume":"81","author":"Romano","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrep.2025.102278_bib114","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib115","first-page":"485","article-title":"Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon drug effectiveness review project","volume":"3","author":"Thaler","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.bbrep.2025.102278_bib116","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Muscoskelet. Disord."},{"key":"10.1016\/j.bbrep.2025.102278_bib117","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human Anti-Interleukin-1\u03b2 monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102278_bib118","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib119","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/children10030434","article-title":"Tocilizumab in juvenile idiopathic arthritis associated uveitis, a narrative review","volume":"10","author":"Iannone","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.bbrep.2025.102278_bib120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/OARRR.S17118","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis","volume":"3","author":"Mihara","year":"2011","journal-title":"Open Access Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102278_bib121","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/PROM.S147286","article-title":"Sarilumab: patient-reported outcomes in rheumatoid arthritis","volume":"9","author":"Crotti","year":"2018","journal-title":"Patient Relat. Outcome Meas."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib122","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/idr14030040","article-title":"Sarilumab administration in COVID-19 patients: literature review and considerations","volume":"14","author":"Marino","year":"2022","journal-title":"Infect. Dis. Rep."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib123","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1759720X17752037","article-title":"Efficacy and safety of sarilumab in patients with active rheumatoid arthritis","volume":"10","author":"McCarty","year":"2018","journal-title":"Ther. Adv. Musculoskelet Dis."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib124","first-page":"200","article-title":"B-cell therapies for rheumatoid arthritis","volume":"70","author":"Scher","year":"2012","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102278_bib125","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib126","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological Anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"issue":"10055","key":"10.1016\/j.bbrep.2025.102278_bib127","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.bbrep.2025.102278_bib128","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar549","article-title":"How does infliximab work in rheumatoid arthritis?","volume":"4","author":"Maini","year":"2002","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib129","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of Infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbrep.2025.102278_bib130","series-title":"Adalimumab","author":"Ellis","year":"2025"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102278_bib131","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00063030-200418020-00005","article-title":"Adalimumab: a review of its use in rheumatoid arthritis","volume":"18","author":"Bang","year":"2004","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib132","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/jcm8030387","article-title":"Golimumab for rheumatoid arthritis","volume":"8","author":"Pelechas","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbrep.2025.102278_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1359571","article-title":"Early identification of golimumab-treated patients with higher likelihood of long-term retention","volume":"15","author":"Garc\u00eda-Dorta","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib134","first-page":"643","article-title":"Real-world effectiveness of golimumab in the treatment of patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis: the GO-BEYOND program","volume":"42","author":"Govoni","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"issue":"10","key":"10.1016\/j.bbrep.2025.102278_bib135","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00296-023-05376-5","article-title":"Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study","volume":"43","author":"Athanassiou","year":"2023","journal-title":"Rheumatol. Int."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102278_bib136","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3390\/life13071601","article-title":"Golimumab for polyarticular juvenile idiopathic arthritis and psoriatic arthritis: pharmacologic and clinical considerations","volume":"13","author":"McIntosh","year":"2023","journal-title":"Life"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102278_bib137","article-title":"The role of etanercept in controlling clinical and radiological progression in rheumatoid arthritis: a systematic review","volume":"16","author":"Ejaz","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bbrep.2025.102278_bib138","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13075-019-1910-2","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib139","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13643-024-02715-w","article-title":"Efficacy, safety, and immunogenicity of biosimilars compared with the biologic etanercept in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Andrade","year":"2024","journal-title":"Syst. Rev."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102278_bib140","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1586\/eci.10.69","article-title":"Certolizumab pegol: a new biologic targeting rheumatoid arthritis","volume":"6","author":"Patel","year":"2010","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102278_bib141","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.bbrep.2025.102278_bib142","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1136\/annrheumdis-2013-203695","article-title":"Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension","volume":"73","author":"Keystone","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrep.2025.102278_bib143","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13075-015-0849-1","article-title":"Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity","volume":"17","author":"Pope","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102278_bib144","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrep.2025.102278_bib145","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221091450","article-title":"Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure","volume":"14","author":"Park","year":"2022","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"10.1016\/j.bbrep.2025.102278_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1502712","article-title":"CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?","volume":"15","author":"Rangel-Pel\u00e1ez","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102278_bib147","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1097\/MS9.0000000000000891","article-title":"Chimeric antigen receptor T cell therapy for the treatment of systemic rheumatic diseases: a comprehensive review of recent literature","volume":"85","author":"Bhandari","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.bbrep.2025.102278_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric antigen receptor T-Cells: an overview of concepts, applications, limitations, and proposed solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102278_bib149","first-page":"878","article-title":"Axicabtagene ciloleucel: the first FDA-Approved CAR T-Cell therapy for relapsed\/refractory large B-Cell lymphoma","volume":"10","author":"King","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib150","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) - an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.bbrep.2025.102278_bib151","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2147\/CMAR.S379807","article-title":"Clinical insights on brexucabtagene autoleucel for the treatment of patients with relapsed or refractory B-Cell acute lymphoblastic leukemia","volume":"16","author":"Kopmar","year":"2024","journal-title":"Cancer Manag. Res."},{"issue":"12","key":"10.1016\/j.bbrep.2025.102278_bib152","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clml.2019.09.598","article-title":"Recent advances in CAR-T cell therapy for non-hodgkin lymphoma","volume":"19","author":"Kallam","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102278_bib153","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.bbrep.2025.102278_bib154","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: Idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrep.2025.102278_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102278_bib156","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"issue":"32","key":"10.1016\/j.bbrep.2025.102278_bib157","article-title":"Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: a systematic review and meta-analysis","volume":"101","author":"Pang","year":"2022","journal-title":"Medicine (Baltim.)"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102278_bib158","doi-asserted-by":"crossref","DOI":"10.1186\/ar1933","article-title":"Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register","volume":"8","author":"Listing","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102278_bib159","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/cr.2009.138","article-title":"Heterogeneity and plasticity of T helper cells","volume":"20","author":"Zhu","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrep.2025.102278_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509956","article-title":"From promise to practice: CAR T and treg cell therapies in autoimmunity and other immune-mediated diseases","volume":"15","author":"Bulliard","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2025.102278_bib162","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3390\/cells13151282","article-title":"Cell-based therapy and genome editing as emerging therapeutic approaches to treat rheumatoid arthritis","volume":"13","author":"Chasov","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib163","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/ijms16010887","article-title":"Cytokine-modulating strategies and newer cytokine targets for arthritis therapy","volume":"16","author":"Venkatesha","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102278_bib164","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s44342-024-00034-z","article-title":"Comprehensive analysis of TCR and BCR repertoires: insights into methodologies, challenges, and applications","volume":"23","author":"Seo","year":"2025","journal-title":"Genomics Inform"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102278_bib165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1759720X16665330","article-title":"Combination therapy with biologic agents in rheumatic diseases: current and future prospects","volume":"8","author":"Inui","year":"2016","journal-title":"Ther. Adv. Musculoskelet Dis."},{"issue":"10","key":"10.1016\/j.bbrep.2025.102278_bib166","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1759720X17720366","article-title":"Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations","volume":"9","author":"Ajeganova","year":"2017","journal-title":"Ther. Adv. Musculoskelet Dis."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825003656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825003656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T17:48:43Z","timestamp":1766598523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580825003656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":166,"alternative-id":["S2405580825003656"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102278","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of T cells and cytokines in the pathogenesis of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102278"}}